98%
921
2 minutes
20
Background: The tumor microenvironment (TME) and migrasomes released by tumor cells significantly influence carcinogenesis and immune evasion. However, our understanding of the prognostic and therapeutic implications of migrasome and tumor microenvironment-related genes (mtmRGs) in head and neck squamous cell carcinoma (HNSCC) remains limited.
Methods: We explored the relationship between mtmRGs and HNSCC prognosis by utilizing The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Subsequently, we developed an innovative prognostic signature, and assessed its prognostic significance using the Kaplan-Meier method, time-dependent receiver operating characteristic (ROC), and Cox regression analyses. To explore the underlying mechanisms, we conducted gene set variation analysis (GSVA), gene set enrichment analysis (GESA), and immune infiltration analysis. A nomogram was developed to estimate the overall survival (OS) rates for HNSCC patients. Lastly, we chose P4HA1, which was part of the signature, for additional experimental validation and .
Results: The mtmRGs signature effectively classifies HNSCC patients into two distinct risk subgroups, with the high-risk cohort demonstrating significantly poorer OS. The risk score serves as an independent prognostic factor for HNSCC patients; those with lower risk scores are more likely to exhibit favorable responses to immunotherapy, particularly with CTLA4 inhibitors. Furthermore, a lower risk score is significantly correlated with the sensitivity of HNSCC patients to cyclophosphamide, gemcitabine, and axitinib.
Conclusion: This study presents an innovative gene signature associated with mtmRGs, which may be utilized both for predicting survival and directing personalized chemotherapy and immunotherapy regiments for patients with HNSCC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/07853890.2025.2558121 | DOI Listing |
Support Care Cancer
September 2025
Department of Oral Pathology, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Purpose: To compare the efficacy of intraoral (IOPBM) and extraoral photobiomodulation (EOPBM) protocols for the prevention and treatment of oral mucositis (OM) in patients with oral or oropharyngeal squamous cell carcinoma (SCC) to submitted radiotherapy (RT).
Methods: This randomized, blinded, multicenter clinical trial enrolled 58 patients with oral or oropharyngeal SCC, who were allocated into two groups matched by treatment type, clinical stage, and RT modality. Group I (IOPBM) received intraoral photobiomodulation (PBM) with a continuous InGaAlP diode laser (660 nm, 100 mW, 0.
Head Neck
September 2025
Department of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, Canada.
Background: Salvage surgery (SS) is one of the best treatment options for recurrent oropharyngeal squamous cell carcinoma (OPSCC) after prior definitive radiation.
Methods: A Medline literature search of articles on open (OSS) and transoral robotic surgery (TORS) for the treatment of recurrent OPSCC was performed. Surgical, functional, and oncological outcomes were analyzed and compared.
Ann Med
December 2025
Department of Immunology, School of Basic Medical Sciences, Henan University, Kaifeng, China.
Background: The tumor microenvironment (TME) and migrasomes released by tumor cells significantly influence carcinogenesis and immune evasion. However, our understanding of the prognostic and therapeutic implications of migrasome and tumor microenvironment-related genes (mtmRGs) in head and neck squamous cell carcinoma (HNSCC) remains limited.
Methods: We explored the relationship between mtmRGs and HNSCC prognosis by utilizing The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases.
Radiother Oncol
September 2025
Dept of Radiation Oncology, Centre Léon Bérard, Lyon, France. Electronic address:
Background And Purpose: To date, no consensus guidelines have been published that systematically guide delineation of primary and nodal Clinical Target Volumes (CTVs) in patients who require post-operative radiotherapy (PORT) for mucosal Head and Neck squamous cell carcinoma (HNSCC). As a result, significant individual, institutional and national variation exists in the way that CTVs are delineated in the post-operative setting, leading to considerable heterogeneity in radiotherapy treatment.
Methods: A multi-disciplinary group of experts convened by the European Society for Radiotherapy and Oncology (ESTRO) set-out principles for the multi-disciplinary management of oral cavity squamous cell carcinoma (OCSCC).
JCO Glob Oncol
May 2025
Grupo Oncoclínicas, São Paulo, Brazil.
Head and neck squamous cell carcinoma (HNSCC) represents a significant public health burden in developing countries, where access to early diagnosis, comprehensive care, and research infrastructure is limited. This article synthesizes the insights generated during a Fireside Chat convened by members of the Latin American Cooperative Oncology Group (LACOG)-Head and Neck and the Brazilian Group of Head and Neck Cancer (GBCP), with the participation of international expert Professor Hisham Mehanna. The discussion addressed key challenges and opportunities in clinical and translational research within resource-constrained settings.
View Article and Find Full Text PDF